Acetyl-L-Carnitine

Acetyl-L-carnitine (ALCAR, ALC, levacecarnine), the acetyl ester of the endogenous quaternary ammonium compound L-carnitine, is a naturally occurring metabolic intermediate synthesized intramitochondrially by carnitine acetyltransferase in essentially all human tissues including brain, liver, heart, kidney, and skeletal muscle. The compound occupies a unique pharmacological position as both an endogenous metabolite with defined physiological roles in mitochondrial energy metabolism and a supplemental or therapeutic agent with a clinical evidence base spanning peripheral neuropathy, major depressive disorder, mild cognitive impairment, Alzheimer disease, and age-related mitochondrial dysfunction. Unlike L-carnitine itself, the acetylated form crosses the blood-brain barrier with substantially greater efficiency and serves as a direct donor of acetyl groups for the synthesis of acetylcholine through the coupled activity of carnitine acetyltransferase and choline acetyltransferase in cholinergic neurons, a property that underwrites much of its central nervous system pharmacology. The molecular pharmacology of ALCAR extends beyond the classical mitochondrial shuttle function. The compound acts as an epigenetic modulator through acetylation of the p65/RelA subunit of the NF-kappaB transcription factor and of histones H3 and H4, leading to upregulation of type 2 metabotropic glutamate (mGlu2) receptor expression at nerve terminals and producing a mechanistically distinct analgesic effect that is not shared by non-acetylated L-carnitine. This epigenetic mechanism, first characterized in models of chronic neuropathic pain, is the molecular basis for the sustained analgesic activity observed in clinical neuropathy trials. ALCAR additionally increases the synthesis and utilization of nerve growth factor (NGF) in the central and peripheral nervous system and promotes peripheral nerve fiber regeneration, properties demonstrated in both aged-animal models and in clinical sural nerve morphometry. The clinical evidence base is substantial. Two large randomized placebo-controlled trials (total intention-to-treat population 1,257 patients) demonstrated that ALCAR at 1,500 to 3,000 mg per day over 52 weeks significantly improved pain scores, nerve fiber regeneration on sural nerve biopsy, and vibratory perception in patients with established diabetic peripheral neuropathy. A systematic review and meta-analysis of randomized controlled trials in peripheral neuropathic pain confirmed significant pain reduction across diabetic, HIV-associated antiretroviral toxic, and chemotherapy-induced neuropathy subtypes. In major depressive disorder, a 2018 meta-analysis of 12 randomized controlled trials (total 791 participants) reported ALCAR supplementation to be significantly superior to placebo and comparably effective to established antidepressants (fluoxetine, amisulpride) with substantially fewer adverse events. A contemporaneous cross-sectional biomarker study identified plasma ALCAR deficiency as a correlate of major depressive disorder severity and earlier age of onset. In mild cognitive impairment and early Alzheimer disease, a meta-analysis of double-blind randomized controlled trials reported a significant advantage for ALCAR over placebo on clinical global impression scales and psychometric testing, though effect sizes were modest and a Cochrane review in the same period concluded that the evidence was insufficient to recommend clinical use. Pharmacokinetics of oral ALCAR are characterized by low bioavailability (less than 10 percent at supplement doses of 0.5 to 1.5 grams, and 14 to 18 percent for L-carnitine at similar doses), with the majority of unabsorbed material subject to gut microbial metabolism to trimethylamine and subsequent hepatic oxidation to trimethylamine N-oxide (TMAO), a metabolite associated in epidemiological studies with cardiovascular risk. The compound is generally well tolerated at oral doses of 1.5 to 3.0 grams per day; the principal adverse events are mild gastrointestinal disturbance, a fishy body odor attributable to trimethylamine production, and insomnia at higher doses. This monograph reviews the chemistry, biosynthesis, and stereochemistry of ALCAR; the mitochondrial, cholinergic, neurotrophic, and epigenetic mechanisms in molecular detail; the comprehensive pharmacokinetic profile including TMAO considerations; the clinical evidence base across neuropathy, depression, cognition, and aging indications; sourcing and quality verification; reconstitution and handling; stack interactions; adverse events; and a structured comparative assessment of five alternative neuroprotective or neuroregenerative compounds against ALCAR on five competency standards.